ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0195 • ACR Convergence 2024

    Screening for Social Determinants of Health in Patients with SLE: A Point-of-Care Feasibility Study

    S. Sam Lim1, Vijay R. Nadipelli2, Michelle Bruno3, Daphne Lew4, Bernard Rubin5, Charmayne M. Dunlop-Thomas6, Kristi R. Mitchell3, Lydia Demetriou7, Jeffrey Berko3 and Alfred Kim8, 1Emory University, Atlanta, GA, 2GSK, Medical Evidence Generation, Philadelphia, PA, 3Atlas Clarity, LLC, San Francisco, CA, 4Center for Biostatistics and Data Science, Institute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine and Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 5Progentec Diagnostics, Inc., Oklahoma City, OK, 6Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, 7GSK, Global Clinical Operations, Brentford, United Kingdom, 8Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO

    Background/Purpose: Currently, social determinants of health (SDoH; conditions in which people live) are not routinely screened for in US outpatient rheumatology clinics.1 SLE disproportionally affects…
  • Abstract Number: 0291 • ACR Convergence 2024

    Safety of Biologic Therapy in Kidney Transplant Recipients with Inflammatory Diseases: Real-world Experience from a Tertiary Medical Center

    Victoria Furer1, Omer Kersh2, Mark Berman3, Ayelet Grupper2 and Ori Elkayam4, 1Tel Aviv Medical Center, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv, Israel, 3Tel Aviv Sourasky Medical Center, Kefar sava, Israel, 4Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Management of solid-organ transplant (SOT) recipients with systemic inflammatory diseases represents a clinical challenge in the paucity of data related to the safety of…
  • Abstract Number: 0258 • ACR Convergence 2024

    Nationwide Analysis of Adult Non-Gonococcal Bacterial Septic Arthritis Hospitalizations from the National Inpatient Sample 2016 to 2020

    Saman Tanveer1, Augustine Manadan2 and Diego Cornejo-Gonzalez3, 1John H. Stroger Jr. Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL, 3John H. Stroger Jr. Hospital of Cook county, Chicago

    Background/Purpose: Septic arthritis is a rheumatologic emergency associated with significant morbidity and mortality. This study examines the descriptive characteristics and risk factors associated with in-hospital…
  • Abstract Number: 0332 • ACR Convergence 2024

    Predictors of Long-term Radiographic Changes in Patients with Idiopathic Inflammatory Myopathies Using Quantitative Imaging Analysis: Real World Experience from a Single Center Longitudinal Cohort

    Sangmee Bae1, Daniela Macrovic2, Auguestine Chung2, Jessica Channick2, Andrea Oh1, Jennifer Wang1, Ani Shahbazian2, Tiffany De Leon2, Yuna Lee2, Grace Kim2, Donald Tashkin2, Jonathan Goldin2 and christina Charles-Schoeman3, 1UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in idiopathic inflammatory myopathies (IIM), and high-resolution computed tomography (HRCT) is a key modality…
  • Abstract Number: 0362 • ACR Convergence 2024

    Development of a Theory-based Digital Messaging Program to Reduce Fatigue in Systemic Lupus Erythematosus

    Anna Deck1, Paula Caras2, Kiran Singh3, Monique Gore-Massy4, Faye Chiu5, Sara Folta6 and Shanthini Kasturi3, 1Tufts University School of Medicine, Portland, ME, 2Tufts University School of Medicine, Boston, MA, 3Tufts Medical Center, Boston, MA, 4Lupus Foundation of America, New Jersey, 5N/A, New York City, NY, 6Tufts University/Tufts University Friedman School of Nutrition, Boston, MA

    Background/Purpose: Fatigue is the single most prevalent symptom of systemic lupus erythematous (SLE), affecting 80-90% of patients, and is often refractory to pharmacologic therapy. Non-pharmacologic…
  • Abstract Number: 0325 • ACR Convergence 2024

    The Impact of Polymyositis and Dermatomyositis in Patients Hospitalized with Inflammatory Bowel Disease: A Nationwide Inpatient Database Analysis

    Pitchaporn Yingchoncharoen1, Nattanicha Chaisrimaneepan2, Jerapas Thongpiya1, Pojsakorn Danpanichkul1 and Yanint Raksadawan3, 1Texas Tech Health Sciences Center, Lubbock, TX, 2Texas Tech University Health Sciences Center, Lubbock, TX, 3Weiss Memorial Hospital, Chicago, IL

    Background/Purpose: Polymyositis and dermatomyositis (PM/DM) are subtypes of idiopathic inflammatory myopathies, belonging to the spectrum of polygenic autoimmune diseases Inflammatory bowel disease (IBD), encompassing ulcerative…
  • Abstract Number: 0319 • ACR Convergence 2024

    Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis

    Farbod Moghaddam1, Mark Tarnopolsky2, Valérie Leclair3, marie Hudson3, Ross Mitchell4, Katherine Buhler1, Erin Hatcher5, Meifeng Zhang1, Antoine Dufour1, Luiz de Almeida1, Marvin Fritzler6 and May Choi1, 1University of Calgary, Calgary, AB, Canada, 2McMaster University, Hamilton, ON, Canada, 3McGill University, Montreal, QC, Canada, 4University of Alberta, Edmonton, Canada, 5McMaster University, Hamilton, Canada, 6Mitogen Diagnostics Corp, Calgary, AB, Canada

    Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…
  • Abstract Number: 0292 • ACR Convergence 2024

    Liver Disease Complicating Familial Mediterranean Fever: A Study on 57 Patients from the French Adult JIR Cohort

    Marion Delplanque1, xavier amiot2, Dominique Wendum3, françois Rodrigues2, Rim bourguiba1, Benoit Terris4, Christophe Duvoux2, Pierre Bedossa5, Didier lebrec5, Philippe Sogni2, Lucia parlati2, Frederic Charlotte2, Vlad Ratziu2, stephane mouly6, jeremy augustin2, julien Calderaro2, giovana scoazec2, JM Vignaud7, JA Seyrig8, Gilles Grateau1, Lea Savey9 and Sophie Georgin-lavialle10, 1Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France, Paris, France, 2APHP, Paris, 3APHP, Paris, France, 4Department of pathology, Hôpital Cochin, GHU Paris Centre, AP-HP, Université Paris Cité,, Paris, France, 5APHP, clichy, 6Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, 7CHRU nancy, Nancy, 8CH centre bretagne, pontivy, 9Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France, france, France, 10Sorbonne Université, Department of internal medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

    Background/Purpose: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease, associated with MEFV gene mutations. FMF patients can experience liver involvement, potentially leading…
  • Abstract Number: 0322 • ACR Convergence 2024

    Enhanced Detection of Myocarditis in Idiopathic Inflammatory Myopathies Utilizing Multiparametric Cardiac Magnetic Resonance Imaging

    Julie Paik1, Shadi Ayoumi2, Ghazal Zandieh2, Cody Calhoun2, Caoilfhionn Connolly2, Lisa Christopher-Stine1, Christopher Mecoli1, Myma Albayda2, Eleni Tiniakou3, Nisha Gilotra2, Stefan Zimmerman2 and Bharath Venkatesh2, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University, Lutherville Timonium, MD

    Background/Purpose: Myocarditis in idiopathic inflammatory myopathies (IIM) is poorly understood despite its association with poor outcomes such as heart failure and sudden cardiac death. It…
  • Abstract Number: 0250 • ACR Convergence 2024

    Effectiveness of Tuberculosis Preventive Treatment in Patients with Rheumatic Diseases: A Global Meta-analysis of Cohort Studies

    Beiming Wang1, Shi Chen2, Xiaoqing Liu3 and Lifan Zhang3, 1Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2Division of Infectious Diseases, Department of Internal medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Peking union medical college hospital, Beijing, China

    Background/Purpose: As patients with rheumatic diseases (RDs) growing into a large population globally, concerns continue exist regarding the potential development of tuberculosis (TB) in this…
  • Abstract Number: 0304 • ACR Convergence 2024

    Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio

    doryan Garcia Olivas1, Judith Hernández Sánchez1, luis Bausá Gimeno1, Javier Nóvoa Medina1, Sergio Machín1, Maria Ángeles Acosta-Mérida1, Diana Botello-Corzo1, daniel Batista Perdomo1, José Ángel Hernández Beriain2 and Beatriz Tejera Segura1, 1Rheumatology Department. Hospital Universitario Insular de Gran Canaria, las Palmas, Spain, 2Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain

    Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of general infection due to the presence of comorbidities, underlying disease activity, and…
  • Abstract Number: 0274 • ACR Convergence 2024

    Cost-effectiveness of Low Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start-Low Go-Slow” Approach for Gout

    Yana Pryymachenko1, Ross Wilson1, Haxby Abbott1, Nicola Dalbeth2 and Lisa Stamp3, 1University of Otago, Dunedin, New Zealand, 2University of Auckland, Auckland, New Zealand, 3University of Otago, Christchurch, Christchurch, New Zealand

    Background/Purpose: To investigate the cost-effectiveness of low-dose colchicine prophylaxis for reducing gout flares when starting allopurinol using the “start-low go-slow” approach.Methods: This was a pre-planned…
  • Abstract Number: 0307 • ACR Convergence 2024

    Mean Metacarpophalangeal Extension to Clinically Quantify Flexor Fibro-inflammatory Hand Involvement in Diabetes

    Sanat Phatak1, Rucha Wagh2, Smita Dhadge2, Sarita Jadhav2, Parth Ladha3, Rishi Nalkande4, Rohan Shah2, Jennifer Ingram5 and Chittaranjan Yajnik2, 1KEM Hospital Research Centre, Pune, Maharashtra, India, 2KEM Hospital Research Centre, Pune, India, 3Byramjee Jeejeebhoy Government Medical College, Pune, Maharashtra, India, 4BJ Government Medical College, Pune, India, 5Duke University Medical Center, Durham, NC

    Background/Purpose: Hand manifestations (limited joint mobility, [LJM]; flexor tenosynovitis, [FT]; carpal tunnel syndrome, [CTS]; Dupuytren disease, [DD]) are common complications in diabetes. Despite their heterogeneity…
  • Abstract Number: 0240 • ACR Convergence 2024

    Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

    Hilde S. Ørbo1, Asia-Sophia Wolf2, Taissa M. Kasahara3, Kristin H. Bjørlykke4, Ingrid Jyssum5, Joseph Sexton5, Anne Therese Tveter5, Guri Solum2, Ingrid Fadum Kjønstad2, Ingrid E. Christensen5, Tore K. Kvien6, Jørgen Jahnsen7, Espen A. Haavardsholm1, Ludvig A. Munthe8, Sella A. Provan5, John Torgils Vaage8, Kristin K. Jørgensen4, Gunnveig Grødeland8, Siri Mjaaland2, Silje W. Syversen9 and Guro L. Goll9, 1Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 2Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, 3University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 4Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 7Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, 8Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…
  • Abstract Number: 0019 • ACR Convergence 2024

    A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles

    Theresa Hunter1, Ferran Soldevila1, Yan Zhang1, Brittany Ross1, Daiki Matsuda1, Yanjie Bao1, John Li1, Michelle Nguyen1, Matthew Butcher1, MIchael Pica1, Claudia Fernandez1, James Vestal1, Goutam Mondal1, Yi Kuo1, Jeffrey Chen1, Josephine Nguyen2, Young Yoon Choi2, Diana Galvan1, Duy Nguyen1, Donald Jhung2, Stuart Sievers1, Steven Tanis1, Cory Bentley2, Michael Rosenzweig1, Priya Karmali1, Adrian Bot1, Haig Aghajanian1 and Gregor Adams1, 1Capstan Therapeutics, San Diego, CA, 2Capstan Therapeutics, San Diego

    Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating clinical efficacy in various autoimmune disease indications. Despite…
  • « Previous Page
  • 1
  • …
  • 61
  • 62
  • 63
  • 64
  • 65
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology